Skip to content
Menu

Ainos, Inc. AIMD

Full chart Compare
Set alert

Price alert · AIMD

All alert types
1.18 USD +0.07 (+6.31%)

Regular-session close

1.15 -0.03 -2.54%

After hours · Nov 20, 7:44 PM ET

1.10 Day range 1.28
0.469 52-week range 3.16
YTD
-28.05%
1 year
-38.22%

5D +0.20 (+21.46%)

0.8011.201.40FriMonTueWedThu1.11
Market cap
8.93M
Revenue (ttm)
40.63K
EPS (ttm)
-2.14
Shares out
14.54M
YTD return
-28.05%
1-year return
-38.22%
50-day average
0.4748
Volume
230.75K
Avg volume
1.87M
Open
1.10
Previous close
1.11
Day's range
1.10 – 1.28
52-week range
0.469 – 3.16
Beta
1.41

Key statistics

200-day average
0.74847
Enterprise value
13.36M
Price / sales
167.25
Price / book
0.36
Free cash flow
621.86K
Total cash
5.16M
Total debt
12.27M
Return on equity
-70.60%
Short % of float
1.44%

Fundamental scorecard

6 of 25 checks passed on AIMD’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 1 of 5
  • Growth 3 of 5
  • Profitability 1 of 5
  • Financial health 1 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
AIMD Revenue — quarterly 642.89K
AIMD Net income — quarterly -1.89M
AIMD EPS — quarterly -0.25

Earnings

AIMD recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 6, 2024Sep 1, 20240.00-0.33——
Aug 5, 2024Jun 1, 20240.00-0.49——
May 13, 2024Mar 1, 20240.00-0.57——
Nov 9, 2023Sep 1, 20230.00-0.75——
Aug 11, 2023Jun 1, 20230.00-0.60——
May 12, 2023Mar 1, 20230.00-0.65——

About Ainos, Inc.

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

Sector
Healthcare
Industry
Medical Devices
Country
United States
Website
ainos.com

News

Your note

Sign in to keep a note on AIMD — it syncs with the Stock Master app.

Insider holders

AIMD insider holders
InsiderRelationLatest transactionDateShares held
CHANG WEN-HANDirectorConversion of Exercise of derivative securityJan 30, 2024106,265
CHIANG YAO-CHUNGDirectorConversion of Exercise of derivative securityJan 30, 202454,932
LEE HSIN LIANG CHRISTOPHERChief Financial OfficerConversion of Exercise of derivative securityNov 25, 202422,376
LEE TING CHUANDirectorConversion of Exercise of derivative securityNov 25, 2024327,432
LIN LAWRENCE KOfficerConversion of Exercise of derivative securityFeb 15, 202411,260
SUNG MENG-LINChief Financial OfficerConversion of Exercise of derivative securityFeb 15, 202461,050

Institution ownership

AIMD institution ownership
Holder% heldSharesValueReported
UBS Group AG0.48%67,00731.31KSep 29, 2024
Virtu Financial LLC0.33%45,22121.13KSep 29, 2024
Geode Capital Management, LLC0.17%23,32110.90KSep 29, 2024
Citadel Advisors Llc0.17%24,05811.24KSep 29, 2024
Blackrock Inc.0.11%15,3257.16KSep 29, 2024
Tower Research Capital LLC (TRC)0.06%8,7634.09KSep 29, 2024

Fund ownership

AIMD fund ownership
Holder% heldSharesValueReported
Fidelity Extended Market Index Fund0.14%19,9519.32KOct 30, 2024
Fidelity Series Total Market Index Fund0.02%3,3051.54KOct 30, 2024
Vanguard Extended Market Index Fund0.01%1,966918Sep 29, 2024
Fidelity NASDAQ Composite Index Fund0.01%1,980925Oct 30, 2024